← Leaderboards
Joshua Weiyuan Wang
Pathovax, Llc
$2,646,422
Attributed
$2,646,422
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2017–20$2M$1.5M$1M$500K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$2,646,422 · 3
By mechanism
R44$2,046,422 · 1
R41$300,000 · 1
R43$300,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Pharmacologic Substance”
- Susan M Landau · University Of California Berkeley$47,252,026
- Gary Fanger · Rise Therapeutics, Llc$20,558,417
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
- Caroline Sigman · Ccs Associates, Inc.$13,846,650
- Vera Hoffman · Reveal Pharma$12,527,604
- Richard Scranton · Lyndra Therapeutics, Inc.$12,106,230
Research focus
Pharmacologic SubstanceTechnologyMalignant NeoplasmsParticleSafetySurfaceGardasilImmunogenicityMeetingsPapillomavirusHuman Papillomavirus 16Human PapillomavirusSmall Business Innovation Research GrantSuccessCapsid ProteinsEpitopesBaseEnsureFormulationClinical TrialsClinically RelevantMouse ModelEfficacy StudyUniversities
Grant awards (5)
Papillomavirus-like Particles (VLP) as Broad Spectrum Human Papillomavirus (HPV) Vaccines$873,677
R44 · FY2020 · AI · contact PI
Papillomavirus-like Particles (VLP) as Broad Spectrum Human Papillomavirus (HPV) Vaccines$873,677
R44 · FY2019 · AI · contact PI
Broad Spectrum Thermostable Single dose Papillomavirus-like Particles (VLP) for the prevention of all HPV-associated cancers.$300,000
R43 · FY2019 · CA · contact PI
Papillomavirus-like Particles (VLP) as Broad Spectrum Human Papillomavirus (HPV) Vaccines$299,068
R44 · FY2018 · AI · contact PI
Polyionic Papillomavirus-like Particles (VLP) for the Treatment of HPV+ oropharyngeal squamous cell carcinomas (OPCs)$300,000
R41 · FY2017 · CA · contact PI